Ventria to Double Biomanufacturing Capacity
The biopharmaceutical company broke ground on what will be a new 3000-ft2 addition to its Kansas biomanufacturing facility.
On Sep. 6, 2017, Ventria Bioscience, a biopharmaceutical company focused on gastrointestinal, autoimmune and infectious diseases, broke ground at its Junction City, KS, site for an expansion of its biomanufacturing and laboratory facilities. The expansion, which represents a more than $1.5-million investment, will roughly double Ventria’s capacity to produce recombinant proteins. Construction on a 3000-ft2 addition to the company’s facilities will begin immediately.
The expansion applies to the company’s molecular biology lab, greenhouses, process development and analytical lab, and processing capacity. Ventria is developing a pipeline of therapeutic proteins, and the company is focusing its therapeutic development effort on treatments for inflammatory bowel disease, such as ulcerative colitis or Crohn's disease. The company also manufactures high-quality, defined, animal-free reagents and cell culture products, and supplies recombinant proteins for development as potential new drugs.
"We are very pleased to announce this expansion. As Ventria's business continues to grow, we are excited about serving our customers and partners globally, as well as contributing to the vibrant economy of Junction City and central Kansas," said Scott Deeter, president and CEO of Ventria, in a company press release. "The proven effectiveness of Ventria's unique technology for biomanufacturing is gaining recognition in our industry, and Ventria's pipeline of therapeutic proteins has the potential to make a real difference in people's health in the future."
Source: Ventria Bioscience
